<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04333160</url>
  </required_header>
  <id_info>
    <org_study_id>000014/BT</org_study_id>
    <nct_id>NCT04333160</nct_id>
  </id_info>
  <brief_title>Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis</brief_title>
  <acronym>JTA-KOA2</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo- and Active-Controlled Phase III Study on the Safety and Efficacy of a Single Intra-articular Administration of JTA-004 in Symptomatic Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bone Therapeutics S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bone Therapeutics S.A</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoarthritis is a degenerative, chronic, and progressive joint disease considered as the&#xD;
      most common joint disorder worldwide. In healthy joints, there is a continuous process of&#xD;
      natural breakdown and repair of cartilage. This process becomes disrupted in OA, leading to&#xD;
      degeneration and loss of articular cartilage, along with other joint changes, including&#xD;
      subchondral bone remodeling, osteophyte formation, thickening of the capsule and sometimes&#xD;
      inflammation of the synovia. JTA-004 is a plasma protein solution supplemented with HA and&#xD;
      clonidine developed as a single IA injection for the treatment of knee OA. Local&#xD;
      administration of JTA-004 into the joint cavity is intended to relieve chronic pain in&#xD;
      subjects suffering from knee OA and discomfort associated with the IA administration.&#xD;
&#xD;
      The JTA-004 Phase III study is a placebo and active-controlled, randomized, double-blind&#xD;
      study to evaluate the potential of a single, intra-articular injection of JTA-004 to reduce&#xD;
      osteoarthritic pain in the knee at 3 months compared to placebo or active comparator. The&#xD;
      study is expected to enrol 742 patients with mild to moderate symptomatic knee osteoarthritis&#xD;
      in 22 centres in 6 European countries and Hong Kong SAR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>knee pain</measure>
    <time_frame>3 months</time_frame>
    <description>Difference between JTA-004 and placebo in mean change from baseline in knee pain at Month 3 using the Western Ontario McMaster University (WOMAC®) Visual Analogue 3.1 pain subscale (subscale A; score 0 (no-pain)-100 (worst imaginable pain) mm).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>knee pain</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between JTA-004 and placebo in mean change from baseline in knee pain at Month 6 using the WOMAC® Visual Analogue 3.1 pain subscale (subscale A; score 0 (no-pain)-100 (worst imaginable pain) mm))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee pain</measure>
    <time_frame>3 months</time_frame>
    <description>Difference between JTA-004 and active comparator in mean change from baseline in knee pain at Month 3 using the WOMAC® Visual Analogue 3.1 pain subscale (subscale A; score 0 (no-pain)-100 (worst imaginable pain) mm))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>knee physical function</measure>
    <time_frame>3 months</time_frame>
    <description>Difference between JTA-004 and placebo in mean change from baseline in knee physical function at Month 3 using the WOMAC® Visual Analogue 3.1 physical function subscale (subscale C; score 0 (no-pain)-100 (worst imaginable pain) mm))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global assessment</measure>
    <time_frame>3 months</time_frame>
    <description>Difference between JTA-004 and placebo in mean change from baseline in Patient Global Assessment at Month 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical function</measure>
    <time_frame>6 months</time_frame>
    <description>Difference between JTA-004 and placebo in mean change from baseline in knee physical function at Month 6 using the WOMAC® Visual Analogue 3.1 physical function subscale (subscale C; 0 (no-pain)-100 (worst imaginable pain) mm))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subject global health and well-being</measure>
    <time_frame>3 months</time_frame>
    <description>Difference between JTA-004 and placebo in mean change from baseline in subject global health and well-being score at Month 3 using the EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>responder rate</measure>
    <time_frame>3 months</time_frame>
    <description>Difference between JTA-004 and placebo in responder rate (defined as ≥ 30% pain intensity reduction) at Month 3</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">746</enrollment>
  <condition>Symptomatic Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>JTA-004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single knee intra-articular injection of JTA-004 solution (2ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single knee intra-articular injection of saline solution (2ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hylan G-F 20</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single knee intra-articular injection of Hylan G-F 20 (6ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTA-004</intervention_name>
    <description>Patients will undergo a single intra-articular injection of JTA-004 into the knee joint</description>
    <arm_group_label>JTA-004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hylan G-F 20</intervention_name>
    <description>Patients will undergo a single intra-articular injection of Hylan G-F 20 into the knee joint</description>
    <arm_group_label>Hylan G-F 20</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will undergo a single intra-articular injection of placebo into the knee joint</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory (able to walk unassisted, the use of a crutch or a walking stick (only one)&#xD;
             is allowed if already used at screening but should be avoided during the study up to&#xD;
             the 6-month follow-up visit)&#xD;
&#xD;
          -  Diagnosed with primary knee OA, fulfilling the following American College of&#xD;
             Rheumatology (ACR) criteria at the target knee:&#xD;
&#xD;
               -  Pain present for most days of the preceding month&#xD;
&#xD;
               -  Morning stiffness &lt; 30 minutes&#xD;
&#xD;
               -  Kellgren-Lawrence grade II or III (confirmed by appropriate X-rays taken within 6&#xD;
                  months prior to screening visit)&#xD;
&#xD;
          -  Target knee pain ≥ 200 mm and ≤ 400 mm out of 500 mm on the WOMAC® VA3.1 pain&#xD;
             questionnaire (sum of 5 questions) at screening and baseline&#xD;
&#xD;
          -  Insufficient/failed response or intolerance to analgesics and/or non-steroidal&#xD;
             anti-inflammatory drugs (NSAIDs) as reported by the subject&#xD;
&#xD;
          -  Willing and able to abstain from initiation of physical therapy and of use of knee&#xD;
             braces at the target knee up to the 6-month follow-up visit (a subject undergoing&#xD;
             physical therapy or using knee braces at a stable frequency for at least 2 weeks prior&#xD;
             to screening is allowed to continue at same frequency (frequency increase is not&#xD;
             allowed))&#xD;
&#xD;
          -  Capable to understand and comply with study requirements and to provide a written,&#xD;
             dated, and signed informed consent prior to any study procedure for participation in&#xD;
             the study and transmission of personal &quot;pseudo-anonymized&quot; data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of trauma or surgery or arthroscopy at the target knee within 12 months before&#xD;
             inclusion&#xD;
&#xD;
          2. Concomitant inflammatory disease or other conditions affecting the joints (e.g.,&#xD;
             infectious arthritis, rheumatoid arthritis, psoriatic arthritis or&#xD;
             spondyloarthropathy, Paget's disease, hemochromatosis…)&#xD;
&#xD;
          3. Any target knee abnormality that could impact safety or efficacy assessment&#xD;
&#xD;
          4. Microcrystalline arthropathies: chondrocalcinosis/calcium pyrophosphate dihydrate&#xD;
             disease (pseudo-gout) or gout if believed likely to interfere with the study&#xD;
             endpoints, in the opinion of the Investigator&#xD;
&#xD;
          5. Clinically significant valgus/varus deformities at the Investigator's discretion&#xD;
&#xD;
          6. Any musculoskeletal condition (such as symptomatic hip OA, amputation, neurologic&#xD;
             disorder, chronic back pain with or without radiculopathy, sciatica) that would impede&#xD;
             measurement of efficacy at target knee&#xD;
&#xD;
          7. Contralateral knee pain equal to or exceeding the pain in the target knee (on the&#xD;
             WOMAC® VA3.1 pain questionnaire) at screening and/or baseline&#xD;
&#xD;
          8. Knee arthroplasty planned within 12 months after the screening visit Current or&#xD;
             previous diagnoses, signs and/or symptoms&#xD;
&#xD;
          9. Uncontrolled diabetes mellitus (hemoglobin A1c [HbA1c] &gt; 10% or &gt; 86 mmol/mol),&#xD;
             end-stage hepatic or renal disease (severe and clinically significant abnormalities&#xD;
             according to local laboratory ranges) documented in the subject's file&#xD;
&#xD;
         10. Any relevant cardiovascular disease (severe coronary insufficiency, conduction&#xD;
             disturbances, recent myocardial infarction, cerebrovascular disease) or any clinically&#xD;
             significant electrocardiogram (ECG) abnormality as judged by the Investigator&#xD;
&#xD;
         11. Subject with neuropathic pain or chronic pain syndrome including fibromyalgia&#xD;
&#xD;
         12. Current (or within the last 5 years prior to entering the study) history of solid or&#xD;
             hematological neoplasia or bone marrow transplantation (except for basal cell&#xD;
             carcinoma and completely excised squamous cell carcinoma)&#xD;
&#xD;
         13. Other severe acute or chronic medical or psychiatric conditions or pre-dispositions or&#xD;
             laboratory abnormalities, as judged by the Investigator&#xD;
&#xD;
         14. Current or past history of coagulation disorders (according to local laboratory&#xD;
             ranges), as judged by the Investigator&#xD;
&#xD;
         15. Hypersensitivity to any components of hyaluronic acid (HA)-based injection products&#xD;
&#xD;
         16. Hypersensitivity to human biological material including blood and blood-derived&#xD;
             products, potential excipients and residues from manufacturing process, documented&#xD;
             clinically or by laboratory tests&#xD;
&#xD;
         17. Hypersensitivity to avian proteins Current or previous treatment&#xD;
&#xD;
         18. Participation in another clinical trial within 3 months prior to screening (within 1&#xD;
             year prior to screening if disease-modifying OA drug (DMOAD) received and if the&#xD;
             Investigator considers it could impact the safety or efficacy assessment)&#xD;
&#xD;
         19. Subject previously treated with JTA-004 within 2 years prior to screening&#xD;
&#xD;
         20. Subject treated with intra-articular viscosupplement or blood-derived product (e.g.,&#xD;
             platelet-rich plasma) injection in the target knee within 6 months prior to screening&#xD;
&#xD;
         21. Subject treated with intra-articular glucocorticoid injection in the target knee&#xD;
             within 4 months prior to screening&#xD;
&#xD;
         22. Subject having started the use of slow acting drugs for OA such as glucosamine,&#xD;
             glucosamine sulfate, chondroitin sulfate, diacerein, curcumin, soybean/avocado&#xD;
             extracts or related products within 1 month prior to screening&#xD;
&#xD;
         23. Current chemo-, radio- or immuno-cancer-therapy or immunosuppressive therapy&#xD;
&#xD;
         24. Chronic (≥ 3 days/week within the last 3 months) use of opioids other than weak&#xD;
             opioids (such as codeine, dihydrocodeine, tramadol…)&#xD;
&#xD;
         25. Chronic (&gt; 15 consecutive days) use of systemic steroids Safety aspects concerning&#xD;
             female subjects of childbearing potential&#xD;
&#xD;
         26. Breast-feeding&#xD;
&#xD;
         27. Pregnancy&#xD;
&#xD;
         28. Woman with positive pregnancy test&#xD;
&#xD;
         29. Woman not willing or not able to use a highly effective contraceptive method during&#xD;
             the 6-month active follow-up period. Highly effective birth control methods are:&#xD;
&#xD;
               1. Combined (estrogen and progestogen containing) hormonal contraception associated&#xD;
                  with inhibition of ovulation (oral, intravaginal, transdermal)&#xD;
&#xD;
               2. Progestogen-only hormonal contraception associated with inhibition of ovulation&#xD;
                  (oral, injectable, implantable)&#xD;
&#xD;
               3. Intrauterine device&#xD;
&#xD;
               4. Intrauterine hormone-releasing system&#xD;
&#xD;
               5. Bilateral tubal occlusion Other exclusion criteria&#xD;
&#xD;
         30. Body Mass Index (BMI) of 40 kg/m2 or greater at baseline&#xD;
&#xD;
         31. Signs of an active drug or alcohol dependence, serious current illness, mental illness&#xD;
             or any other factors which may interfere with subject's ability to understand and&#xD;
             comply with study requirements, as judged by the Investigator&#xD;
&#xD;
         32. Life expectancy less than 12 months at screenin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc (UCL)</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ambroise Paré</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Brno, s.r.o</name>
      <address>
        <city>Brno</city>
        <zip>60200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Czech, a.s</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Prague s.r.o</name>
      <address>
        <city>Praha</city>
        <zip>13000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Parker Institute</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanos Clinic</name>
      <address>
        <city>Gandrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanos Clinic</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanos Clinic</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hong Kong Center for Clinical Research</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Timofei Mosneaga&quot; Republican Clinical Hospital, Sectia Reumatologie,</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RTL SM SRL / Institutul de Cardiologie, sectia consultativa</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL35</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL37</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL36</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL31</name>
      <address>
        <city>Nadarzyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL32</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL33</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PL34</name>
      <address>
        <city>Świdnica</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Pancras Clinical Research</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Hong Kong</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2020</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hylan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

